Adam B. Johnson

Adam B. Johnson

Auto-generated profile, based on publicly available information

Adam B. Johnson

University of Arkansas for Medical Sciences

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Techniques in Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AJAdam B. Johnson
Adam B. Johnson
GRGresham T. Richter
Gresham T. Richter

1 December 2018 in Clinics in Perinatology
Verified
Journal Article
Closed access
AJAdam B. Johnson
Adam B. Johnson
GRGresham T. Richter
Gresham T. Richter

Verified
Journal Article
Open access
PDF file
SRSunhyo Ryu
Sunhyo Ryu
YLYonghee Lee
Yonghee Lee
MHMoo Yeol Hyun
Moo Yeol Hyun
SCSun Young Choi
Sun Young Choi
Kwan Ho JeongKwan Ho Jeong
Kwan Ho Jeong
Beomjoon KimBeomjoon Kim
Beomjoon Kim
Recently, various immunosuppressant drugs have been shown to induce hair growth in normal hair as well as in alopecia areata and androgenic alopecia; however, the responsible mechanism has not yet been fully elucidated. In this study, we investigate the influence of mycophenolate (MPA), an immunosuppressant, on the proliferation of human dermal papilla cells (hDPCs) and on the growth of human hair follicles following catagen induction with interferon (IFN)-γ. IFN-γ was found to reduce β-catenin, an activator of hair follicle growth, and activate glycogen synthase kinase (GSK)-3β, and enhance expression of the Wnt inhibitor DKK-1 and catagen inducer transforming growth factor (TGF)-β2. IFN-γ inhibited expression of ALP and other dermal papillar cells (DPCs) markers such as Axin2, IGF-1, and FGF 7 and 10. MPA increased β-catenin in IFN-γ-treated hDPCs leading to its nuclear accumulation via inhibition of GSK3β and reduction of DKK-1. Furthermore, MPA significantly increased expression of ALP and other DPC marker genes but inhibited expression of TGF-β2. Therefore, we demonstrate for the first time that IFN-γ induces catagen-like changes in hDPCs and in hair follicles via inhibition of Wnt/β-catenin signaling, and that MPA stabilizes β-catenin by inhibiting GSK3β leading to increased β-catenin target gene and DP signature gene expression, which may, in part, counteract IFN-γ-induced catagen in hDPCs.

6 July 2021 in Facial Plastic Surgery & Aesthetic Medicine
Verified
Journal Article
Closed access
TSThomas Ples Spradley
Thomas Ples Spradley
AJAdam B. Johnson
Adam B. Johnson
HWHeather D. Wright
Heather D. Wright
JKJay M. Kincannon
Jay M. Kincannon
GRGresham T. Richter
Gresham T. Richter
Background: Venous malformations (VMs) are congenital vascular malformations that grow progressively and never resolve on their own. Cutaneous VMs are difficult to treat due to risk of injury and deformation. The purpose of this study was to examine the safety and efficacy of a modified neodymium-doped yttrium aluminum garnet laser (modified ND:YAG) in the management of cutaneous VMs. Methods: Retrospective chart review of patients undergoing modified ND:YAG therapy for cutaneous VMs and a blind prospective evaluation of photographs, performed by 10 reviewers, before and after treatment for growth, stability, improvement, or resolution of VMs. Results: Forty-five patients (18 males and 27 females) who underwent modified ND:YAG therapy for a cutaneous VM were identified. Based on photographic review, modified ND:YAG therapy elicited improvement in the appearance of VMs in 72% of the patients, χ 2 (1, N = 45) = 25.94, p < 0.0001, with reviewers noting complete resolution in 8.2%, significant improvement in 34.5%, some improvement in 29.3%, and no growth or improvement in 20.9% of patients. Growth of the VM was noted in 7.3% of patients. Three (6.7%) patients reported complications from the treatment, which included infection, bleeding, blister, and color change. Four patients (8.9%) reported pretreatment pain, which resolved in three (75.0%) after treatment. Conclusions: Modified ND:YAG therapy can provide safe and effective treatment for cutaneous VMs and should be considered in the multimodal management of VMs.

26 April 2023 in Human Mutation
Verified
Journal Article
Open access
PDF file
YZYuri A. Zarate
Yuri A. Zarate
KBKatherine Bosanko
Katherine Bosanko
AKAmrit Kannan
Amrit Kannan
ATAshlen Thomason
Ashlen Thomason
BNBeth Nutt
Beth Nutt
ACAisling Caffrey
Aisling Caffrey
Characterized by developmental delay with severe speech delay, dental anomalies, cleft palate, skeletal abnormalities, and behavioral difficulties, SATB2-associated syndrome (SAS) is caused by pathogenic variants in SATB2. The SAS phenotype range of severity has been documented previously in large series. Using data from the SAS registry, we present the SAS severity score, a comprehensive scoring rubric that encompasses 15 different individual neurodevelopmental and systemic features. Higher (more severe) systemic and total (sum of neurodevelopmental and systemic scores) scores were seen for null variants located after amino acid 350 (the start of the CUT1 domain), the recurrent missense Arg389Cys variant ( ), intragenic deletions, and larger chromosomal deletions. The Arg389Cys variant had the highest cognitive, verbal, and sialorrhea severity scores, while large chromosomal deletions had the highest expressive, ambulation, palate, feeding and growth, neurodevelopmental, and total scores. Missense variants not located in the CUT1 or CUT2 domain scored lower in several subcategories. We conclude that the SAS severity score allows quantitative phenotype morbidity description that can be used in routine clinical counseling. Further refinement and validation of the SAS severity score are expected over time. All data from this project can be interactively explored in a new portal.

9 September 2024 in The Cleft Palate Craniofacial Journal
Verified
Journal Article
Closed access
PFPatricia M Fuentes
Patricia M Fuentes
SFSoroush Farsi
Soroush Farsi
JGJose A. Garcia
Jose A. Garcia
WNWassim Najjar
Wassim Najjar
AJAdam Johnson
Adam Johnson
Usama S. HamdanUsama S. Hamdan
Usama S. Hamdan
Introduction: Postoperative feeding is crucial for the recovery of children after cleft surgery. The literature outlines diverse feeding methods with varying recommendations on the duration of non-nipple feeding postsurgery. This study aims to explore reported postoperative feeding modalities for infants undergoing primary cleft lip/palate repair, concentrating on their influence on feeding improvement and complication reduction. Methods: PubMed, Cochrane, and Web of Science databases were queried for original English articles without any date restrictions. This review was conducted in accordance with the 2020 PRISMA. The MINORS criteria was used to assess quality of studies. Results: Of 696 abstracts, 9 full-text articles were included, consisting of 459 children with cleft lip (n = 221) & cleft lip/palate (n = 238). Feeding modalities included bottle, breastfeeding, spoon, syringe, and nasogastric tube. Two studies found a significant increase in weight with breastfeeding compared to spoon or cup. Two studies found partial wound dehiscence using spoons, and two studies reported dehiscence using bottles. Post-palatoplasty, two studies showed a decrease in hospital stay in infants breastfed (2.1 & 5.8 days) vs spoon-fed (6 days). Analgesia was reduced in the breastfed group vs spoon/nasogastric tube. Conclusion: This review highlights the importance of postoperative feeding in the recovery of infants with cleft lip/palate. Evidence suggests that breastfeeding may offer advantages in terms of weight gain and reduced hospital stay, while potentially minimizing the need for postoperative analgesia. The limited number of studies and variability in their outcomes underscore the need for further research to establish evidence-based guidelines for postoperative feeding.